Involvement of Kruppel-like factor 9 in bleomycin-induced pulmonary toxicity

Gu,Yue; Wu,Yan‑Bing; Wang,Li‑Hui; Yin,Jia‑Ning

doi:10.3892/mmr.2015.4015

Involvement of Kruppel-like factor 9 in bleomycin-induced pulmonary toxicity

Authors:
- Yue Gu
- Yan‑Bing Wu
- Li‑Hui Wang
- Jia‑Ning Yin
View Affiliations

Affiliations: Department of Respiratory and Critical Care Medicine, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, Department of Respiratory and Critical Care Medicine, Beijing Chao‑Yang Hospital Affiliated to Capital Medical University, Beijing 100020, P.R. China, Department of Pediatrics, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: July 2, 2015 https://doi.org/10.3892/mmr.2015.4015
Pages: 5262-5266

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxidative stress or the production of reactive oxygen species (ROS) has been implicated as an important factor in the development of bleomycin (BLM)-induced pulmonary toxicity; however, the mechanism behind the toxicity remains to be elucidated. The present study aimed to investigate the key factor involved in BLM‑induced toxicity. The study was conducted in human pulmonary fibroblast (HPF) cells and in a mouse model. The ROS level, cell death assay, protein and gene expression levels of Kruppel‑like factor 9 (Klf9) and other associated factors were assessed. A dose‑dependent increase in ROS, lipid peroxidation, cell death, and protein and mRNA expression levels of NF‑E2‑related transcription factor 2 (Nrf2) and Klf9 were observed in BLM‑treated cells. However, the expression levels of the other antioxidant proteins assessed, including catalase, super oxide dismutase, glutathione reductase and thioredoxin reductase 2, were decreased. The expression levels of Nrf2 were decreased in cells treated with a higher concentration (>200 µM) of BLM. These results suggested that in response to increased intracellular levels of ROS, above a critical threshold, Nrf2 stimulates the expression of Klf9, resulting in a further increase in Klf9‑mediated ROS production and subsequent cell death. Furthermore, the data suggested that Klf9 may be considered as an adjunctive therapeutic target for BLM-induced pulmonary toxicity.

View Figures

View References

1	Karam H, Hurbain-Kosmath I and Housset B: Antioxidant activity in alveolar epithelial type 2 cells of rats during the development of bleomycin injury. Cell Biol Toxicol. 14:13–22. 1998. View Article : Google Scholar : PubMed/NCBI
2	Patel RB, Kotha SR, Sauers LA, Malireddy S, Gurney TO, Gupta NN, Elton TS, Magalang UJ, Marsh CB, Haley BE, et al: Thiol-redox antioxidants protect against lung vascular endothelial cytoskeletal alterations caused by pulmonary fibrosis inducer, bleomycin: Comparison between classical thiol-protectant, N-acetyl-L-cysteine and novel thiol antioxidant, N,N′-bis-2-mercaptoethyl isophthalamide. Toxicol Mech Methods. 22:383–396. 2012. View Article : Google Scholar : PubMed/NCBI
3	Lazo JS and Chabner BA: Cancer chemotherapy and biotherapy: principles and practice. Chabner BA and Longo DL: Philadelphia: Lippincott-Raven; pp. 379–394. 1996
4	Hecht SM: Bleomycin: New perspectives on the mechanism of action. J Nat Prod. 63:158–168. 2000. View Article : Google Scholar : PubMed/NCBI
5	Chandler DB: Possible mechanisms of bleomycin-induced fibrosis. Clin Chest Med. 11:21–30. 1990.PubMed/NCBI
6	Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY and Strieter RM: IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J Immunol. 163:5686–5692. 1999.PubMed/NCBI
7	Finkel T and Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature. 408:239–247. 2000. View Article : Google Scholar : PubMed/NCBI
8	Cross CE, Warren D, Gerriets JE, Wilson DW, Halliwell B and Last JA: Deferoxamine injection does not affect bleomycin induced lung fibrosis in rats. J Lab Clin Med. 106:433–438. 1985.PubMed/NCBI
9	Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD and Yamamoto M: Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 13:76–86. 1999. View Article : Google Scholar : PubMed/NCBI
10	Wasserman WW and Fahl WE: Functional antioxidant responsive elements. Proc Natl Acad Sci USA. 94:5361–5366. 1997. View Article : Google Scholar : PubMed/NCBI
11	Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, et al: An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 236:313–322. 1997. View Article : Google Scholar : PubMed/NCBI
12	Kikuchi N, Ishii Y, Morishima Y, Yageta Y, Haraguchi N, Itoh K, Yamamoto M and Hizawa N: Nrf2 protects against pulmonary fibrosis by regulating the lung oxidant level and Th1/Th2 balance. Respir Res. 11:312010. View Article : Google Scholar : PubMed/NCBI
13	Mannava S, Zhuang D, Nair JR, Bansal R, Wawrzyniak JA, Zucker SN, Fink EE, Moparthy KC, Hu Q, Liu S, et al: KLF9 is a novel transcriptional regulator of bortezomib- and LBH589-induced apoptosis in multiple myeloma cells. Blood. 119:1450–1458. 2012. View Article : Google Scholar :
14	Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 72:248–254. 1976. View Article : Google Scholar : PubMed/NCBI
15	Serrano-Mollar A, Closa D, Prats N, Blesa S, Martinez-Losa M, Cortijo J, Estrela JM, Morcillo EJ and Bulbena O: In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats. Br J Pharmacol. 138:1037–1048. 2003. View Article : Google Scholar : PubMed/NCBI
16	Mastruzzo C, Crimi N and Vancheri C: Role of oxidative stress in pulmonary fi brosis. Monaldi Arch Chest Dis. 57:173–176. 2002.
17	Mata M, Ruiz A, Cerda M, Martinez-Losa M, Cortijo J, Santangelo F, Serrano-Mollar A, Llombart-Bosch A and Morcillo EJ: Oral N-acetylcysteine reduces bleomycininduced lung damage and mucin Muc5ac expression in rats. Eur Respir J. 22:900–905. 2003. View Article : Google Scholar : PubMed/NCBI
18	Cheresh P, Kim SJ, Tulasiram S and Kamp DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta. 1832:1028–1040. 2013. View Article : Google Scholar :
19	Sayed-Ahmed MM, Mansour HH, Gharib OA and Hafez HF: Acetyl-L-carnitine modulates bleomycin-induced oxidative stress and energy depletion in lung tissues. J Egypt Natl Canc Inst. 16:237–243. 2004.
20	Ali EN and Mansour SZ: Boswellic acids extract attenuates pulmonary fi brosis induced by bleomycin and oxidative stress from gamma irradiation in rats. Chin Med. 6:362011. View Article : Google Scholar
21	Iraz M, Erdogan H, Kotuk M, Yagmurca M, Kilic T, Ermis H, Fadillioğlu E and Yildirim Z: Ginkgo biloba inhibits bleo-mycin-induced lung fi brosis in rats. Pharmacol Res. 53:310–316. 2006. View Article : Google Scholar : PubMed/NCBI
22	Erdogan H, Fadillioglu E, Kotuk M, Iraz M, Tasdemir S, Oztas Y and Yildirim Z: Effects of Ginkgo biloba on plasma oxidant injury induced by bleomycin in rats. Toxicol Ind Health. 22:47–52. 2006. View Article : Google Scholar : PubMed/NCBI
23	Cho HY, Reddy SP, Yamamoto M and Kleeberger SR: The transcription factor NRF2 protects against pulmonary fibrosis. FASEB J. 18:1258–1260. 2004.PubMed/NCBI
24	Bieker JJ: Krüppel-like factors: Three fingers in many pies. J Biol Chem. 276:34355–34358. 2001. View Article : Google Scholar : PubMed/NCBI
25	Mouratis MA and Aidinis V: Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med. 17:355–361. 2011. View Article : Google Scholar : PubMed/NCBI